• Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

How Syngene supported a clinical-stage oncology company in manufacturing the RSM for treating a rare tumour

Learn how Syngene reduced the number of steps required to synthesize an RSM for two API candidates by 50% and successfully manufactured and supplied the GMP product to the client.

Author

Latest Blogs

AI technology concept with capsules and tablets, representing the role of AI in toxicology and computational toxicology for predictive drug safety.

Computational toxicology – The new frontier in predictive safety assessment

Close-up of a scientist holding a blue-and-white capsule, symbolizing dose optimization in oncology research under Project Optimus.

Project Optimus – Transforming the paradigm of dose optimization and selection in oncology Introduction

Preparative HPLC peptide purification with solvent recovery

Peptide synthesis and the hidden complexities of scaling peptide therapeutics

How to choose a CRDMO at CPHI Frankfurt 2025: A Fieldguide

Syngene Enables Orocidin to Achieve Clinically Acceptable Antimicrobial Peptide

DMPK Unravelled: Breaking barriers in drug discovery

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details